{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T16:14:23Z","timestamp":1758039263698,"version":"3.44.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T00:00:00Z","timestamp":1683676800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.ad.2023.02.022","type":"journal-article","created":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T11:30:40Z","timestamp":1683718240000},"page":"T494-T501","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["[Translated article] Updated Position of the Spanish Psoriasis Group (GPs) on the Use of Biosimilar Drugs in Moderate to Severe Psoriasis"],"prefix":"10.1016","volume":"114","author":[{"given":"R.","family":"Ruiz-Villaverde","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Gal\u00e1n-Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Llamas-Velasco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Salgado-Boquete","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Puig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"de la Cueva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.M.","family":"Carrascosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ad.2023.02.022_bib0170","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.ad.2020.03.008","article-title":"Biosimilars in the treatment of psoriasis: an update","volume":"111","author":"Puig","year":"2020","journal-title":"Actas Dermosifiogr"},{"key":"10.1016\/j.ad.2023.02.022_bib0175","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.ad.2015.04.006","article-title":"Biosimilars in dermatology: current situation (Part I)","volume":"106","author":"Puig","year":"2015","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2023.02.022_bib0180","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/cpt.1653","article-title":"Advancing biosimilar development using pharmaco-dynamic biomarkers in clinical pharmacology studies","volume":"107","author":"Li","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ad.2023.02.022_bib0185","first-page":"249","article-title":"The use of biosimilar drugs in psoriasis: a position paper","volume":"106","author":"Carretero","year":"2015","journal-title":"Actas Dermosifilogr"},{"key":"10.1016\/j.ad.2023.02.022_bib0190","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.2147\/DDDT.S317382","article-title":"An update review of biosimilars of adalimumab in psoriasis \u2013 bioequivalence and interchangeability","volume":"15","author":"Zhou","year":"2021","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.ad.2023.02.022_bib0195","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1001\/jamadermatol.2021.0221","article-title":"Outcomes following a mandatory nonmedical switch from adalimumab originator to adalimumab biosimilars in patients with psoriasis","volume":"157","author":"Loft","year":"2021","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ad.2023.02.022_bib0200","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/bjd.17133","article-title":"Etanercept biosimilar SB4 in the treatment of chronic plaque psoriasis: data from the Psobiosimilars registry","volume":"180","author":"Gisondi","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2023.02.022_bib0205","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1080\/09546634.2019.1610553","article-title":"Anti-TNF biosimilars in psoriasis: from scientific evidence to real-world experience","volume":"31","author":"Barker","year":"2020","journal-title":"J Dermatol Treat"},{"key":"10.1016\/j.ad.2023.02.022_bib0210","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1080\/14712598.2020.1798924","article-title":"Biosimilars in psoriasis: what should your positioning be?","volume":"21","author":"Ruiz-Villaverde","year":"2021","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.ad.2023.02.022_bib0215","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1080\/14712598.2019.1636963","article-title":"Biosimilars for the treatment of psoriasis","volume":"19","author":"Puig","year":"2019","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.ad.2023.02.022_bib0220","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1111\/bcp.15101","article-title":"Switching between reference adalimumab and biosimilars in chronic immune-mediated inflammatory diseases: a systematic literature review","volume":"88","author":"Garc\u00eda-Beloso","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ad.2023.02.022_bib0225","first-page":"1","article-title":"Switching and discontinuation patterns among patients stable on originator infliximab who switched to an infliximab biosimilar or remained on originator infliximab","volume":"15","author":"Fitzgerald","year":"2021","journal-title":"Biologics"},{"key":"10.1016\/j.ad.2023.02.022_bib0230","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1111\/bjd.15152","article-title":"The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis","volume":"176","author":"Griffiths","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2023.02.022_bib0235","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/bjd.16890","article-title":"Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches","volume":"179","author":"Blauvelt","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2023.02.022_bib0240","doi-asserted-by":"crossref","first-page":"3399","DOI":"10.1002\/art.22193","article-title":"Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials","volume":"54","author":"Zink","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ad.2023.02.022_bib0245","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.jid.2017.09.044","article-title":"Differential drug survival of second-line biologic therapies in patients with psoriasis: observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)","volume":"138","author":"Iskandar","year":"2018","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.ad.2023.02.022_bib0250","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s40261-021-01089-4","article-title":"Health economic assessment of optimal biological treatment for moderate-to-severe psoriasis","volume":"41","author":"Barker","year":"2021","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.ad.2023.02.022_bib0255","first-page":"e15831","article-title":"Drug survival of adalimumab biosimilars in real-world treatment of psoriasis: a Spanish multi-centre study","author":"L\u00f3pez-Ferrer","year":"2022","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.ad.2023.02.022_bib0260","first-page":"199","article-title":"Efficacy and safety of anti-TNF biosimilars for psoriasis in pediatric and geriatric populations: a 72-week real-life study","volume":"12","author":"Megna","year":"2022","journal-title":"Psoriasis (Auckl)"},{"key":"10.1016\/j.ad.2023.02.022_bib0265","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1111\/1346-8138.16508","article-title":"Safety, efficacy, and drug survival of the infliximab biosimilar CT-P13 in post-marketing surveillance of Japanese patients with psoriasis","volume":"49","author":"Morita","year":"2022","journal-title":"J Dermatol"},{"key":"10.1016\/j.ad.2023.02.022_bib0270","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s40259-019-00394-x","article-title":"Immunogenicity of biosimilars for rheumatic diseases plaque psoriasis, and inflammatory bowel disease: a review from clinical trials and regulatory documents","volume":"34","author":"Strand","year":"2020","journal-title":"BioDrugs"},{"key":"10.1016\/j.ad.2023.02.022_bib0275","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.jaad.2016.12.014","article-title":"Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: a randomized, double-blind, multicenter, phase III study","volume":"76","author":"Papp","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2023.02.022_bib0280","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1136\/annrheumdis-2021-219961","article-title":"Biological disease-modifying antirheumatic drugs may mitigate the risk of psoriatic arthritis in patients with chronic plaque psoriasis","volume":"81","author":"Gisondi","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ad.2023.02.022_bib0285","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1136\/annrheumdis-2021-220865","article-title":"Treating the skin with biologics in patients with psoriasis decreases the incidence of psoriatic arthritis","volume":"81","author":"Acosta Felquer","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ad.2023.02.022_bib0290","unstructured":"Available from: https:\/\/www.seimc.org\/ficheros\/documentoscientificos\/otrosdeinteres\/seimc-dc-2013-PosicionamientodeBiosimilaresAsebio.pdf\/1521-1463."},{"key":"10.1016\/j.ad.2023.02.022_bib0295","unstructured":"Available from: https:\/\/seom.org\/seomcms\/images\/stories\/recursos\/Posicionamiento_sobre_biosimilares_mayo_2018.pdf."},{"key":"10.1016\/j.ad.2023.02.022_bib0300","unstructured":"Available from: https:\/\/www.ser.es\/wp-content\/uploads\/2018\/01\/POSICIONAMIENTO-SER-2018.pdf."},{"key":"10.1016\/j.ad.2023.02.022_bib0305","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.reuma.2015.03.009","article-title":"Documento de poscionamiento de la Sociedad Espa\u00f1ola de Reumatolog\u00eda sobre f\u00e1rmacos biosimilares","volume":"11","author":"Abad Hern\u00e1ndez","year":"2015","journal-title":"Reumatol Clin"},{"key":"10.1016\/j.ad.2023.02.022_bib0310","unstructured":"Available from: https:\/\/seioc-uveitis.com\/wp-content\/uploads\/2019\/05\/documento_de_posicionamiento_de_la_sociedad_espa%C3%B1ola_de_inflamacion_ocular_sobre_farmacos_biosimilares.pdf."},{"key":"10.1016\/j.ad.2023.02.022_bib0315","unstructured":"Available from: https:\/\/revistafarmaciahospitalaria.sefh.es\/gdcr\/index.php\/fh\/article\/view\/10973."},{"year":"2012","series-title":"La Regulaci\u00f3n del precio de los medicamentos en base al valor","author":"Rovira","key":"10.1016\/j.ad.2023.02.022_bib0320"},{"key":"10.1016\/j.ad.2023.02.022_bib0325","unstructured":"Ministerio de Hacienda y Funci\u00f3n P\u00fablica. Serie Gasto Farmac\u00e9utico y Sanitario: per\u00edodo junio-2014 a marzo-2018. Ministerio de Hacienda y Funci\u00f3n P\u00fablica. SERIE Gasto Farmac\u00e9utico y Sanitario: per\u00edodo junio-2014 a marzo-2018."},{"key":"10.1016\/j.ad.2023.02.022_bib0330","article-title":"Switching from reference adalimumab to biosimilar assessment of clinical outcomes in psoriasis","author":"Ruiz-Villaverde","year":"2022","journal-title":"Int J Dermatol"}],"container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731023003460?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731023003460?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T01:16:12Z","timestamp":1757553372000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001731023003460"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S0001731023003460"],"URL":"https:\/\/doi.org\/10.1016\/j.ad.2023.02.022","relation":{},"ISSN":["0001-7310"],"issn-type":[{"type":"print","value":"0001-7310"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"[Translated article] Updated Position of the Spanish Psoriasis Group (GPs) on the Use of Biosimilar Drugs in Moderate to Severe Psoriasis","name":"articletitle","label":"Article Title"},{"value":"Actas Dermo-Sifiliogr\u00e1ficas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2023.02.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2023.02.016","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 AEDV. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}